Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands
- PMID: 11312114
- DOI: 10.1016/s1359-6101(00)00030-7
Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands
Abstract
Skeletal mass is maintained by a balance between cells which resorb bone (osteoclasts) and cells which form bone (osteoblasts). Bone development and growth is an on-going, life-long process. Bone is formed during embryonic life, grows rapidly through childhood, and peaks around 20 years of age (formation exceeds resorption). For humans the skeleton then enters a long period, approximately 40 years, when bone mass remains relatively stable. Skeletal turnover continues but the net effect of resorption and formation on bone mass is zero. For women this ends when they enter menopause and similar bone loss occurs for men, but later in life. These opposite functions are coupled, resorption precedes formation, and osteoblasts, or their precursors, stromal cells, regulate osteoclast formation and activity. Until recently, the molecular nature of this regulation, was poorly understood. However, recent observations have identified members of the TNF family of ligands and receptors as critical regulators of osteoclastogenesis. Osteoprotegerin (OPG) a decoy receptor was first identified. Its ligand, receptor activator of nuclear factor-kappaB ligand (RANKL), was quickly found, and shown to be expressed on stromal cells and osteoblasts. Its cognate receptor, RANK, was found to be expressed in high levels on osteoclast precursors. The interaction between RANKL and RANK was shown to be required for osteoclast formation. These observations have provided a molecular understanding of the coupling between osteoclastic bone resorption and osteoblastic bone formation. Moreover, they provide a framework on which to base a clear understanding of normal (e.g. postmenopausal osteoporosis and age associated bone loss) and pathologic skeletal changes (e.g. osteopetrosis, glucocorticoid-induced osteoporosis, periodontal disease, bone metastases, Paget's disease, hyperparathyroidism, and rheumatoid arthritis).
Similar articles
-
Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.J Bone Miner Res. 2005 Sep;20(9):1659-68. doi: 10.1359/JBMR.050503. Epub 2005 May 2. J Bone Miner Res. 2005. PMID: 16059637
-
Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology.J Mol Med (Berl). 2001 Jun;79(5-6):243-53. doi: 10.1007/s001090100226. J Mol Med (Berl). 2001. PMID: 11485016 Review.
-
Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption.J Bone Miner Res. 2005 Dec;20(12):2224-32. doi: 10.1359/JBMR.050803. Epub 2005 Aug 1. J Bone Miner Res. 2005. PMID: 16294275
-
Expression of osteoprotegerin, receptor activator of NF-kappaB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing.J Bone Miner Res. 2001 Jun;16(6):1004-14. doi: 10.1359/jbmr.2001.16.6.1004. J Bone Miner Res. 2001. PMID: 11393777
-
RANKL-RANK signaling in osteoclastogenesis and bone disease.Trends Mol Med. 2006 Jan;12(1):17-25. doi: 10.1016/j.molmed.2005.11.007. Epub 2005 Dec 13. Trends Mol Med. 2006. PMID: 16356770 Review.
Cited by
-
Adenoviral vector-mediated overexpression of osteoprotegerin accelerates osteointegration of titanium implants in ovariectomized rats.Gene Ther. 2015 Aug;22(8):636-44. doi: 10.1038/gt.2015.34. Epub 2015 Apr 14. Gene Ther. 2015. PMID: 25871826
-
Amelioration of rat adjuvant-induced arthritis by Met-RANTES.Arthritis Rheum. 2005 Jun;52(6):1907-19. doi: 10.1002/art.21033. Arthritis Rheum. 2005. PMID: 15934086 Free PMC article.
-
A diet containing high- versus low-daidzein does not affect bone density and osteogenic gene expression in the obese Zucker rat model.Food Funct. 2019 Oct 16;10(10):6851-6857. doi: 10.1039/c9fo01292c. Food Funct. 2019. PMID: 31580380 Free PMC article.
-
The role of RANKL and FGF23 in Assessing Bone Turnover in Type 2 Diabetic Patients.Acta Endocrinol (Buchar). 2021 Apr-Jun;17(1):51-59. doi: 10.4183/aeb.2021.51. Acta Endocrinol (Buchar). 2021. PMID: 34539910 Free PMC article.
-
Inhibiting myostatin signaling prevents femoral trabecular bone loss and microarchitecture deterioration in diet-induced obese rats.Exp Biol Med (Maywood). 2016 Feb;241(3):308-16. doi: 10.1177/1535370215606814. Epub 2015 Oct 5. Exp Biol Med (Maywood). 2016. PMID: 26438721 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources